GALEZ Stock Overview
Operates as a healthcare service provider in Switzerland and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for GALEZ from our risk checks.
Galenica AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 76.75 |
| 52 Week High | CHF 78.18 |
| 52 Week Low | CHF 69.30 |
| Beta | 0.18 |
| 11 Month Change | 2.68% |
| 3 Month Change | 6.30% |
| 1 Year Change | 6.89% |
| 33 Year Change | 19.46% |
| 5 Year Change | n/a |
| Change since IPO | 78.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| GALEZ | GB Healthcare | GB Market | |
|---|---|---|---|
| 7D | 2.2% | 0.6% | 2.2% |
| 1Y | 6.9% | -22.6% | 8.0% |
Return vs Industry: GALEZ exceeded the UK Healthcare industry which returned -23.5% over the past year.
Return vs Market: GALEZ matched the UK Market which returned 6.6% over the past year.
Price Volatility
| GALEZ volatility | |
|---|---|
| GALEZ Average Weekly Movement | 1.9% |
| Healthcare Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: GALEZ has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: GALEZ's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1927 | 7,955 | Marc Werner | www.galenica.com |
Galenica AG operates as a healthcare service provider in Switzerland and internationally. It operates through two segments, Products & Care, and Logistics & IT. The Products & Care segment operates pharmacies and partner pharmacies under the Amavita, Sun Store, and Coop Vitality brands.
Galenica AG Fundamentals Summary
| GALEZ fundamental statistics | |
|---|---|
| Market cap | CHF 3.84b |
| Earnings (TTM) | CHF 169.68m |
| Revenue (TTM) | CHF 3.80b |
22.7x
P/E Ratio1.0x
P/S RatioIs GALEZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GALEZ income statement (TTM) | |
|---|---|
| Revenue | CHF 3.80b |
| Cost of Revenue | CHF 3.34b |
| Gross Profit | CHF 464.58m |
| Other Expenses | CHF 294.90m |
| Earnings | CHF 169.68m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Mar 11, 2025
| Earnings per share (EPS) | 3.41 |
| Gross Margin | 12.22% |
| Net Profit Margin | 4.46% |
| Debt/Equity Ratio | 42.9% |
How did GALEZ perform over the long term?
See historical performance and comparison